Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 19,060 Shares

Posted by Micah Haroldson on Apr 3rd, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $14.45, for a total transaction of $275,417.00. Following the completion of the sale, the chief operating officer directly owned 451,540 shares in the company, valued at approximately $6,524,753. The trade was a 4.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.83, for a total value of $263,599.80.
On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.37, for a total value of $254,832.20.
On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.18, for a total value of $251,210.80.
On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.41, for a total value of $255,594.60.
On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.29, for a total transaction of $1,881,638.07.
On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $12.96, for a total transaction of $247,017.60.
On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.79, for a total transaction of $457,617.39.
On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.68, for a total transaction of $285,672.80.
On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total transaction of $484,845.47.
On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $16.00, for a total transaction of $495,056.00.

Adaptive Biotechnologies Price Performance

Shares of ADPT stock traded up $0.38 during midday trading on Thursday, reaching $14.81. 1,565,438 shares of the company traded hands, compared to its average volume of 2,063,705. The firm’s 50 day simple moving average is $15.53 and its two-hundred day simple moving average is $15.92. The firm has a market cap of $2.28 billion, a PE ratio of -37.02 and a beta of 2.19. Adaptive Biotechnologies Corporation has a 1-year low of $6.68 and a 1-year high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The company’s revenue was up 51.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.23) EPS. As a group, research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Adaptive Biotechnologies

Institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd purchased a new position in shares of Adaptive Biotechnologies during the fourth quarter valued at approximately $28,000. Sound Income Strategies LLC acquired a new position in Adaptive Biotechnologies in the 3rd quarter valued at $30,000. EverSource Wealth Advisors LLC raised its holdings in Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after acquiring an additional 1,565 shares during the last quarter. Assetmark Inc. lifted its stake in shares of Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the period. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies during the 4th quarter worth $51,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ADPT. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Guggenheim increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th. TD Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Finally, JPMorgan Chase & Co. upped their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.25.

View Our Latest Research Report on ADPT

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.